Drug Profile
Caffeine citrate - Mead Johnson
Alternative Names: CafcitLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Mead Johnson
- Class Respiratory stimulants; Small molecules; Xanthines
- Mechanism of Action Phosphoric diester hydrolase inhibitors; Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Apnoea
Most Recent Events
- 03 Jan 2008 Caffeine citrate licensed to Bedford Laboratories
- 15 May 2003 Mead Johnson, a Bristol-Myers Squibb subsidiary, has purchased Cafcit® from OPR Development
- 31 Dec 2000 Launched for Apnoea in USA (PO)